CHE 110.64 Chemed Inc $CHE Hit a 52 week high of 111.00

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
CHE 110.64 Chemed Inc $CHE Hit a 52 week high of 111.00 Closing the day 09:43 at 110.64 +0.64 +0.58% With a day low of 109.68 and a total volume of 4,563.

CHE Recent Posts: http://investorshangout.com/Chemed-Corp-CHE-50503/

CHE Chemed Inc Recent Headline News

OJSC Cherkizovo Group: 9 Months 2014 Financial Results Announcement
Marketwired - Wed Nov 12, 5:09AM CST
OJSC Cherkizovo Group (LSE: CHE)
CHE: 109.98 (-0.02)

Chemed's board reports 174th consecutive quarterly dividend of USD0.22 per share
M2 - Mon Nov 10, 8:17AM CST
The board of directors of Chemed (NYSE:CHE), a hospice care company, on Friday declared a quarterly dividend of USD0.22 per share on the company's capital stock.
CHE: 109.98 (-0.02)

Chemed Corporation declares $0.22 dividend
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 12:41PM CST

CHE: 109.98 (-0.02)

Chemed Corporation Declares Quarterly Dividend of 22 Cents
Business Wire - Fri Nov 07, 12:18PM CST
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 22 cents per share on the Company's capital stock, payable on December 8, 2014, to shareholders of record as of November 17, 2014. This represents the 174th consecutive quarterly dividend paid by Chemed in its 43 years as a public company.
CHE: 109.98 (-0.02)

Amsurg's Q3 Earnings Top on Revenue Growth, View Raised - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 11:20AM CST
Amsurg Corp. (AMSG) reported third-quarter 2014 adjusted earnings per share (EPS) of 66 cents from continuing operations.
CHE: 109.98 (-0.02), AMSG: 50.30 (-0.12), RDNT: 8.48 (+0.13), AMED: 25.57 (+0.46)

Chemed Corporation to Present at the 2014 Credit Suisse Healthcare Conference
Business Wire - Tue Nov 04, 12:23PM CST
Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the 2014 Credit Suisse Healthcare Conference on Tuesday, November 11, 2014, at approximately 11:30 a.m. (MT) at the Arizona Biltmore Hotel in Phoenix, AZ.
CHE: 109.98 (-0.02)

Chemed's (CHE) CEO Timothy O'Toole on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Oct 31, 9:10PM CDT

CHE: 109.98 (-0.02)

Chemed posts 3Q profit
Automated Insights - Thu Oct 30, 5:13PM CDT
CINCINNATI (AP) _ Chemed Corp. (CHE) on Thursday reported profit of $24.6 million in its third quarter.
CHE: 109.98 (-0.02)

Chemed misses by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 4:20PM CDT

CHE: 109.98 (-0.02)

Chemed Reports Third-Quarter 2014 Results
Business Wire - Thu Oct 30, 3:01PM CDT
Chemed Corporation (Chemed) (NYSE:CHE), which operates VITAS Healthcare Corporation (VITAS), the nation's largest provider of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2014, versus the comparable prior-year period, as follows:
CHE: 109.98 (-0.02)

Notable earnings after Thursday’s close
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:35PM CDT

ELLI: 41.12 (-0.27), AIV: 36.43 (+0.32), EPAY: 25.69 (unch), CPSI: 62.78 (+0.09), LNKD: 233.91 (+2.78), ADNC: 3.98 (-0.04), CODE: 21.50 (+0.19), HME: 63.64 (+0.34), ESIO: 7.36 (+0.07), HIL: 4.01 (-0.02), DGI: 28.04 (-0.28), AHT: 10.60 (-0.64), COLM: 40.98 (+0.16), AHS: 16.43 (-0.19), CSLT: 11.93 (-0.22), FRT: 132.63 (+1.16), DGII: 7.54 (-0.05), ADUS: 21.47 (+0.21), ESS: 201.47 (+1.03), EXPE: 87.02 (-0.09), IMPV: 45.21 (+0.56), CCI: 81.21 (+0.70), CPT: 76.02 (+0.46), GB: 50.48 (+0.29), AEGR: 21.16 (-0.15), ATEN: 4.12 (unch), ELGX: 11.94 (+0.08), AFFX: 10.00 (+0.22), CHE: 109.98 (-0.02), BCOV: 7.07 (-0.04), DCT: 8.43 (+0.03), ELX: 5.52 (-0.05), GNMK: 11.55 (+0.07), AXTI: 2.43 (+0.03), INT: 44.13 (-0.39), EGN: 66.98 (-1.72), EGO: 5.84 (+0.09), GMED: 23.16 (unch), GDOT: 21.89 (-0.31), KEG: 2.52 (-0.07), ISBC: 10.84 (-0.03), GRPN: 7.89 (-0.21), ALJ: 16.48 (-0.50), CTRL: 15.06 (+0.14), GPRO: 77.65 (+0.80), EMN: 83.90 (-0.16), IMMR: 8.96 (-0.28), CUBE: 20.95 (+0.19), BYI: 81.51 (+0.47), ATRC: 18.48 (+0.24), BYD: 11.97 (+0.18), FLDM: 30.35 (+0.46), BEAT: 8.43 (+0.16), FLR: 65.16 (-0.79), FLT: 148.72 (+1.32), EHTH: 24.10 (-0.32)

Chemed To Report Third-Quarter 2014 Earnings October 30, Related Conference Call To Be Held On October 31
Business Wire - Fri Oct 17, 10:55AM CDT
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the third quarter ended September 30, 2014, on Thursday, October 30, 2014, following the close of trading on the New York Stock Exchange.
CHE: 109.98 (-0.02)

Chemed Has Returned 13.9% Since SmarTrend Recommendation (CHE)
Comtex SmarTrend(R) - Wed Oct 01, 11:15AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on June 6th, 2014 at $90.14. In approximately 4 months, Chemed has returned 13.90% as of today's recent price of $102.66.
CHE: 109.98 (-0.02)

14.0% Return Seen to Date on SmarTrend Chemed Call (CHE)
Comtex SmarTrend(R) - Wed Sep 24, 9:56AM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on June 6th, 2014 at $90.14. In approximately 4 months, Chemed has returned 14.00% as of today's recent price of $102.75.
CHE: 109.98 (-0.02)

Humana Hits 52-Week High on Buyback Approval, ACO Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 8:50AM CDT
On Sep 19, 2014, shares of Humana Inc. (HUM) scaled a 52-week high of $135.10 on the back of a number of positive tidings at the company.
CNC: 97.47 (-0.03), CHE: 109.98 (-0.02), MCO: 100.73 (+0.65), HUM: 138.77 (+1.52)

WellPoint's (WLP) Increased Membership Raises Optimism - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:50PM CDT
On Sep 17, 2014, we issued an updated research report on WellPoint Inc. (WLP).
CNC: 97.47 (-0.03), CHE: 109.98 (-0.02), GTS: 23.32 (-0.05), WLP: 127.86 (+1.22)

Insider Trading Alert - LIN, CONN And CHE Traded By Insiders
at The Street - Fri Sep 12, 9:15AM CDT
Stocks with insider trader activity include LIN, CONN and CHE
CHE: 109.98 (-0.02), CONN: 31.93 (-0.36), LIN: 23.82 (+0.17)

Shares of CHE Up 17.5% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 5:04PM CDT
SmarTrend identified an Uptrend for Chemed (NYSE:CHE) on June 6th, 2014 at $90.14. In approximately 3 months, Chemed has returned 17.53% as of today's recent price of $105.94.
CHE: 109.98 (-0.02)

HMS Holdings (HMSY) Slumps: Stock Falls by 10.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 7:34AM CDT
HMS Holdings (HMSY) fell by over 10% in the last trading session amid huge volumes, reversing its recent uptrend, as the stock is now up over 9% since Aug 7.
CHE: 109.98 (-0.02), AMED: 25.57 (+0.46), HMSY: 21.63 (unch), RGDO: 0.86 (-0.02)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

What to Expect: Your First Therapy Session Insights

Updated Category News Views 220

Starting With the Unknown: The Therapy Journey Begins Rolling into that first therapy session can feel like walking into a mystery with no clues. You're not alone if it stirs up some nerves—most folks feel the same, especially when it's your first rodeo in mental health support. That's where Cody Luke and David Spencer of Luke and Spencer Behavioral Health, based out in...

Continue Reading
CapCut's Role in AI-Assisted Small Biz Marketing

Updated Category News Views 0

In today's fast-paced digital world, small businesses lament the constant hustle to stay relevant online. This juggling act with limited resources often makes effective marketing feel like a high-wire circus performance. Enter AI tools, promising to lighten the load, and CapCut stands out as a game-changer. AI Tools Revolutionizing Small Business Marketing Amid growing...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 90

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 228

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 408

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
TORRAS Cases Balance Protection with Slim Design for 2026

Updated Category News Views 39

Are Slim iPhone Cases Really Protecting Your Investment? Anyone who's dropped a brand-new phone knows the pain of watching your investment smack the concrete. But hey, welcome to 2026, where Consumer365's latest rundown on iPhone protective gear turns the spotlight on TORRAS. These folks grabbed attention with their Q3 Air and Q3 Air Pro cases, crafted for iPhone 18 Pro...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 237

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading

Top 5 Most Recently Viewed Articles

SoftBank Expands AI Infrastructure with DigitalBridge Deal

Updated Category News Views 109

SoftBank's Strategic Move in AI Infrastructure SoftBank Group Corp. has recently announced its plans to acquire DigitalBridge Group Inc. in a cash deal worth approximately $4 billion. This move is seen as a pivotal step in SoftBank's commitment to scaling its infrastructure capabilities for artificial intelligence globally. Details of the Acquisition Under the terms of...

Continue Reading
Nio's Bold Moves in the EV Space: What Investors Should Know

Updated Category News Views 158

Forget the Noise, Nio's Got a Game Plan Back in my day, when you heard whispers about a new product launch, it was either a cause for celebration or a catastrophe waiting to happen. Nio, the fast-rising EV player from China, is set to drop its ES9 SUV this May, and trust me, eyes are on the road. They’ve laid out the details like a clear roadmap. Mark Your Calendars Qin...

Continue Reading
Graycliff Partners Declares Landmark Structures Sale to Cerberus

Updated Category News Views 166

Graycliff Partners Announces the Sale of Landmark Structures Graycliff Partners LP has revealed its decision to sell Landmark Structures, an esteemed provider of water and industrial storage infrastructure solutions, to Cerberus Capital Management, a robust investment firm with a global reach. Landmark Structures specializes in designing, manufacturing, and installing...

Continue Reading
Wedbush Recognizes Uber Technologies as a Top Investment

Updated Category News Views 229

Wedbush Identifies Uber Technologies as a Prime Investment Opportunity In a recent analysis, Wedbush has included Uber Technologies Inc (NYSE: UBER) in its prestigious 'best ideas list.' This recognition stems from the company's attractive risk/reward dynamics, particularly as its shares are trading at a lower multiple. Valuation Insights Currently, Uber's stock is...

Continue Reading
Ververica Enhances Global Impact Through Innovative Partnerships

Updated Category News Views 161

Ververica's Global Influence in Real-Time Data Streaming Ververica, the pioneers behind Apache Flink®, recently highlighted its expanding global impact during the Flink Forward Jakarta event. This flagship occasion, known for focusing on cutting-edge data streaming technologies, served as an excellent platform for Ververica to demonstrate its dedication to helping...

Continue Reading